JP2022536486A5 - - Google Patents

Info

Publication number
JP2022536486A5
JP2022536486A5 JP2021573298A JP2021573298A JP2022536486A5 JP 2022536486 A5 JP2022536486 A5 JP 2022536486A5 JP 2021573298 A JP2021573298 A JP 2021573298A JP 2021573298 A JP2021573298 A JP 2021573298A JP 2022536486 A5 JP2022536486 A5 JP 2022536486A5
Authority
JP
Japan
Prior art keywords
less
vedolizumab
composition
ppm
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573298A
Other languages
English (en)
Japanese (ja)
Other versions
JP7624414B2 (ja
JP2022536486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037059 external-priority patent/WO2020252069A1/en
Publication of JP2022536486A publication Critical patent/JP2022536486A/ja
Publication of JP2022536486A5 publication Critical patent/JP2022536486A5/ja
Priority to JP2024218770A priority Critical patent/JP2025063035A/ja
Application granted granted Critical
Publication of JP7624414B2 publication Critical patent/JP7624414B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573298A 2019-06-10 2020-06-10 抗α４β７抗体の産生方法 Active JP7624414B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024218770A JP2025063035A (ja) 2019-06-10 2024-12-13 抗α４β７抗体の産生方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859494P 2019-06-10 2019-06-10
US62/859,494 2019-06-10
PCT/US2020/037059 WO2020252069A1 (en) 2019-06-10 2020-06-10 METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024218770A Division JP2025063035A (ja) 2019-06-10 2024-12-13 抗α４β７抗体の産生方法

Publications (3)

Publication Number Publication Date
JP2022536486A JP2022536486A (ja) 2022-08-17
JP2022536486A5 true JP2022536486A5 (https=) 2024-02-09
JP7624414B2 JP7624414B2 (ja) 2025-01-30

Family

ID=73781728

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573298A Active JP7624414B2 (ja) 2019-06-10 2020-06-10 抗α４β７抗体の産生方法
JP2024218770A Pending JP2025063035A (ja) 2019-06-10 2024-12-13 抗α４β７抗体の産生方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024218770A Pending JP2025063035A (ja) 2019-06-10 2024-12-13 抗α４β７抗体の産生方法

Country Status (14)

Country Link
US (1) US20220267449A1 (https=)
EP (1) EP3980466A4 (https=)
JP (2) JP7624414B2 (https=)
CN (3) CN114375307B (https=)
AR (1) AR119270A1 (https=)
AU (1) AU2020290943A1 (https=)
BR (1) BR112021024897A2 (https=)
CA (1) CA3143167A1 (https=)
IL (1) IL288825A (https=)
MA (1) MA56129A (https=)
MX (1) MX2021015300A (https=)
PL (1) PL439809A1 (https=)
TW (1) TW202112818A (https=)
WO (1) WO2020252069A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433947B2 (en) 2018-04-10 2025-10-07 Dr. Reddy's Laboratories Limited Stable formulations of therapeutic antibody
WO2019198099A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Stable antibody formulation
WO2023007516A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy’S Laboratories Limited Method to control high molecular weight aggregates in an antibody composition
EP4380948A4 (en) * 2021-08-05 2025-07-16 Dr Reddys Laboratories Ltd METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY
WO2023031965A1 (en) * 2021-09-03 2023-03-09 Dr. Reddy’S Laboratories Limited Method to obtain a purified antibody composition
WO2024233992A2 (en) * 2023-05-11 2024-11-14 Trophogen, Inc. Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
PL3116891T3 (pl) * 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Similar Documents

Publication Publication Date Title
JP2022536486A5 (https=)
JP5814951B2 (ja) 免疫グロブリン溶液を精製するための方法
JP7624414B2 (ja) 抗α４β７抗体の産生方法
US10400042B2 (en) Method for increasing pyro-glutamic acid formation of a protein
EA012162B1 (ru) Способ рефолдинга рекомбинантных антител
US4558005A (en) Monoclonal anti-erythropoietin
JP7817743B2 (ja) タンパク質の精製の改善されたプロセス
JP2019504060A (ja) モノクローナル抗体のアイソフォームを分離するための方法
US20250296014A1 (en) An improved process of purification of protein
JP2618618B2 (ja) 抗ｇ−ｃｓｆ誘導体、ｎｄ２８モノクローナル抗体
US20260117000A1 (en) Process of purification of protein
US20260103542A1 (en) Process of purification of protein
US20260116917A1 (en) Process of purification of protein
RU2852606C2 (ru) СПОСОБЫ ПОЛУЧЕНИЯ АНТИТЕЛА ПРОТИВ α4β7
US20250296015A1 (en) An improved process of purification of protein
RU2021139493A (ru) СПОСОБЫ ПОЛУЧЕНИЯ АНТИТЕЛЛА ПРОТИВ α4β7
JPS6342472A (ja) 抗インスリン様成長因子２モノクロ−ナル抗体、その製造法およびその使用法
HK1176946B (en) Method for purifying immunoglobulin solutions